Matched Unrelated Donor Stem Cell Transplantation (MUD-SCT) After Dose-reduced Conditioning for Patients With Multiple Myeloma and Relapse After Autologous SCT
NCT00599495 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50
Last updated 2022-09-02
Summary
The purpose of this study is to determine whether a reduced intensity conditioning regimen followed by allogeneic stem cell transplantation from unrelated donors is a feasible and effective treatment for patients with multiple myeloma who failed a previous autologous stem cell transplantation.
Conditions
Interventions
- PROCEDURE
-
allogeneic HSCT
dose-reduced conditioning regimen
Sponsors & Collaborators
-
Universitätsklinikum Hamburg-Eppendorf
lead OTHER
Principal Investigators
-
Nicolaus Kroeger, Prof. Dr. · Universitätsklinikum Hamburg-Eppendorf
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Max Age
- 60 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2002-11-30
- Primary Completion
- 2009-08-31
- Completion
- 2009-12-31
Countries
- Germany
Study Locations
More Related Trials
-
Reduce Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed Multiple Myeloma
NCT04205240 ·Status: TERMINATED ·Phase: PHASE2
-
Auto-Allo Tandem Stem Cell Transplantation for Patients With Multiple Myeloma
NCT00777998 ·Status: COMPLETED ·Phase: PHASE2
-
Tandem Autologous- Nonmyeloablative Allogeneic Transplant for Newly Diagnosed Multiple Myeloma (Trapianto Tandem Autologo-Allogenico Non Mieloablativo Nel Mieloma Alla Diagnosi)
NCT00702247 ·Status: UNKNOWN ·Phase: PHASE2
-
Autologous or Syngeneic Stem Cell Transplant Followed by Donor Stem Cell Transplant and Bortezomib in Treating Patients With Newly Diagnosed High-Risk, Relapsed, or Refractory Multiple Myeloma
NCT00793572 ·Status: COMPLETED ·Phase: PHASE2
-
Allogeneic Stem Cell Transplantation vs. Conventional Therapy as Salvage Therapy for Relapsed / Progressive Patients With Multiple Myeloma After First-line Therapy
NCT05675319 ·Status: TERMINATED ·Phase: PHASE3
-
Bortezomib Before Donor Stem Cell Transplant in Treating Patients With Multiple Myeloma
NCT00995059 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
MEDI-551 as Maintenance Therapy After Allogeneic Stem Cell Transplant in Multiple Myeloma
NCT03218163 ·Status: TERMINATED ·Phase: PHASE2
-
Primary Multiple Myeloma Who Achieved MRD Negativity After Induction Therapy, ASCT or Not
NCT06463717 ·Status: RECRUITING
-
High-Dose Melphalan and a Second Stem Cell Transplant or Low-Dose Cyclophosphamide in Treating Patients With Relapsed Multiple Myeloma After Chemotherapy
NCT00747877 ·Status: UNKNOWN ·Phase: PHASE3
-
Autologous Transplantation for Multiple Myeloma
NCT00378222 ·Status: COMPLETED ·Phase: PHASE3
-
Biological Therapy in Treating Patients With Multiple Myeloma That Has Recurred Following Bone Marrow Transplantation
NCT00003153 ·Status: COMPLETED ·Phase: PHASE2
-
Assessment of Allogeneic Hematopoietic Cell Transplantation in Medicare Beneficiaries With Multiple Myeloma
NCT03127761 ·Status: RECRUITING
-
Combination Chemotherapy and Donor Stem Cell Transplant Followed by Ixazomib Citrate Maintenance Therapy in Treating Patients With Relapsed High-Risk Multiple Myeloma
NCT02504359 ·Status: COMPLETED ·Phase: PHASE1
-
Tandem Melphalan and Autolog. SCT in MM Patients 60 to 70 Years of Age With and Without Induction Chemotherapy
NCT02288741 ·Status: COMPLETED ·Phase: PHASE3
-
Autologous Transplant for Multiple Myeloma
NCT00177047 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Haploidentical Bone Marrow Stem Cell Transplantation in Patients With Multiple Myeloma
NCT02519114 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Study of Melphalan and Topotecan (MT) Followed by Autologous Stem Cell Rescue in Patients With Multiple Myeloma.
NCT00325416 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
NCT00075829 ·Status: COMPLETED ·Phase: PHASE3
-
Mixed Chimera Allogeneic Transplantation From Matched Unrelated Donors For The Treatment Of Multiple Myeloma
NCT00185653 ·Status: COMPLETED ·Phase: NA
-
a Clinical Trial of Efficacy and Safety of the Holistic Treatment of Young High-risk Multiple Myeloma Patients
NCT04008888 ·Status: UNKNOWN ·Phase: NA
-
Trial of ID-Specific Donor Vaccinated Lymphocyte Infusion for Patients With Myeloma Relapsing or Failing to Achieve a Complete Remission After an Allogenic Transplant
NCT01174082 ·Status: TERMINATED ·Phase: PHASE2
-
Early Response-adapted Intensification of Induction Chemotherapy in Patients With Newly Diagnosed Multiple Myeloma (MM)
NCT01114048 ·Status: UNKNOWN ·Phase: PHASE2
-
Tandem Auto Stem Cell Transplant With Melphalan Followed by Melphalan and Bortezomib in Patients With Multiple Myeloma
NCT01241708 ·Status: COMPLETED ·Phase: PHASE3
-
Tandem High Dose Melphalan Versus Triple Intermediate Dose Melphalan and Stem Cell Transplantation in Induction Phase and Prednisolone/IFN Versus IFN in Maintenance Therapy
NCT00205764 ·Status: COMPLETED ·Phase: PHASE3
-
Stopping Maintenance Therapy in People With Multiple Myeloma in MRD-Negative Remission
NCT04221178 ·Status: ACTIVE_NOT_RECRUITING